Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade

Exclusion Criteria

• •Severe renal disease
• •Pregnant or nursing
• •Proteinuria \>8g/g creatinine or \>8g/day
• •Systemic manifestations of Henoch-Schonlein purpura within 2 years prior
• •Patients with Immunoglobulin A nephropathy deemed secondary to underlying disease
• •Biopsy reported severe crescentic Immunoglobulin A nephropathy
• •History of treatment with glucocorticoids, cyclophosphamide, azathioprine, mycophenolate mofetil, or any biologic immunomodulatory agent with 24 weeks prior
• •History of clinically significant cardiac conditions
• •History of cancer within 5 years prior
• •Any infection requiring antibiotic treatment that has not cleared prior to study start